17-AAG

Bioviotica
Product Code: BVT-0244
Supplier: Bioviotica

CodeSizePrice
BVT-0244-C100100 ug£35.00
Quantity:
BVT-0244-M0011 mg£55.00
Quantity:
BVT-0244-M0055 mg£90.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
20°C
Storage:
-20°C

Images

1 / 1
Chemical Structure

Chemical Structure

Further Information

Alternate Names/Synonyms:
17-(Allylamino)-17-desmethoxygeldanamycin
Appearance:
Red to dark red powder.
CAS:
75747-14-7
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Handling Advice:
Protect from light when in solution.
Hazards:
H302, H312, H319
InChi:
InChI=1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24?,25+,27+,29?/m1/s1
InChiKey:
AYUNIORJHRXIBJ-DDSLGTNESA-N
Long Description:
Chemical. CAS: 75747-14-7. Formula: C31H43N3O8. MW: 585.7. Semi-synthetic derivative from geldanamycin. Potent, less toxic analog of geldanamycin (Prod. No. BVT-0196). Inhibits the essential ATPase activity of HSP90. Telomerase activity inhibitor. Apoptosis inducer. Antitumor compound.
MDL:
MFCD04973892
Molecular Formula:
C31H43N3O8
Molecular Weight:
585.7
Package Type:
Plastic Vial
Precautions:
P270, P280, P301, P312, P302, P352, P312
Product Description:
Potent, less toxic analog of geldanamycin (Prod. No. BVT-0196). Inhibits the essential ATPase activity of HSP90. Telomerase activity inhibitor. Apoptosis inducer. Antitumor compound.
Purity:
>98% (HPLC)
Signal word:
Warning
SMILES:
[H]/C1=C([H])/[C@H](OC)[C@@H](OC(N)=O)C(C)=C[C@H](C)[C@H](O)[C@H](C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)C(C)=C1)C2=O)OC
Solubility Chemicals:
Soluble in DMSO (10 mg/ml) or methanol (10 mg/ml).
Source / Host:
Semi-synthetic derivative from geldanamycin.
Transportation:
Non-hazardous
UNSPSC Category:
Natural Products/Extracts
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C. After reconstitution protect from light at -20°C.

References

Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives: R.C. Schnur, et al.; J. Med. Chem. 38, 3806 (1995) | The benzoquinoneansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin: T.W. Schulte & L.M. Neckers; Cancer Chemother. Pharmacol. 42, 273 (1998) | Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone: P.A. Clarke, et al.; Oncogene 19, 4125 (2000) | Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts: R. Nimmanapalli, et al.; Cancer Res. 61, 1799 (2001) | A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors: A. Kamal, et al.; Nature 425, 407 (2003) | Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction: I.A. Vasilevskaya, et al.; Cancer Res. 63, 3241 (2003) | Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells: R. Villa, et al.; Carcinogenesis 24, 851 (2003) | Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model: C.R. Williams, et al.; J. Urol. 178, 1528 (2007) | Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers: R.K. Ramanathan, et al.; Clin. Cancer Res. 13, 1769 (2007) | An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxy- geldanamycin and carboplatin in human ovarian cancer models: U. Banerji, et al.; Cancer Chemother. Pharmacol. 62, 769 (2008) | HSP90 inhibitor 17AAG causes apoptosis in ATRA-resistant acute pro-myelocytic leukemia cells: P.N. Meyer, et al.; Leuk. Res. 32, 143 (2008) | Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis: J. Madrigal-Matute, et al.; Cardiovascular Res. 86, 330 (2010)

Related Products

Product NameProduct CodeSupplier